Click on the name of the speaker to download the slide deck

Keynote Session: “The Future of Advanced Therapies”

• Peter Goodfellow, Scientific Advisor, Abingworth
  “Regenerating the Future, Again”
• Lord James O’Shaughnessy, Parliamentary Under Secretary of State for Health (Lords), UK Government
• Ian Campbell, Director for Health and Life Sciences, Innovate UK
  “Innovate UK Supporting Research Development & Manufacturing in Advanced Therapies”
• Christian K Schneider, Director, National Institute for Biological Standards and Control (NIBSC)
  “Advanced Therapies – regulatory challenges”

Building Effective R&D Partnerships to Accelerate ATMPs

• Seigo Izumo, Senior Vice President for Regenerative Medicine, Takeda Pharmaceuticals
• Eduardo Bravo, Chief Executive Officer, TiGenix; EBE President
• Qasim Rafiq, Senior Lecturer (Associate Professor) in Bioprocessing of Regenerative, Cellular and Gene Therapies, UCL
• Keith Thompson, Chief Executive Officer, Cell and Gene Therapy Catapult

ATMPs as Cures – The Opportunities and Challenges for Europe

• Michaël Hocquemiller, Scientific Director, Lysogene
  “Pioneering gene therapies for CNS disorders”
• Adrien Lemoine, VP Business Development & Operations, Orchard Therapeutics
  “Overcoming the complex challenges associated with the development of ex vivo gene therapies for rare diseases”
• Karen Hodgkin, Chief Operating Officer, Cell Medica
  “Cell Medica: Novel approaches for the treatment of Solid Tumours”
• James McBlane, CAT Alternate Member, Preclinical Assessor, UK Medicines and Healthcare Products Regulatory Agency (MHRA)
  “Partnering well together – creating a global ecosystem for advanced therapies”

R&D and Commercialisation 2020 – Maximising the Value of European Innovation

• Magda Papadaki, Head of Product and Process Innovation, Association of the British Pharmaceutical Industry (ABPI)
• Barbara Freischem, Executive Director, European Biopharmaceutical Enterprises (EBE)
• Deborah Morrison, Senior Scientific Adviser, National Institute for Health and Care Excellence (NICE)
• Michael Stein, Chief Executive Officer and Chairman, Oxstem Ltd

Click edit button to change this text.